INmune Bio Inc logo

INmune Bio Inc(INMB)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.05
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for INMB

11/13/2026: INMB (1-star) is currently NOT-A-BUY. Pass it for now.

INmune Bio Inc is a clinical-stage biotechnology company focused on developing immunotherapies that target innate immune dysfunction and chronic inflammation. Its primary strengths reside in promising late-stage clinical assets like the CORDStrom platform for RDEB and XPro for neuroinflammation, supported by favorable regulatory alignments. The core investment story centers on its potential transition into a commercial-stage organization via upcoming international and domestic regulatory filings. However, the company faces substantial risks, including continuous cash burn, lack of significant commercial revenues, and intense biotechnology competition. The stock suits growth-oriented or speculative investors willing to assume binary clinical and regulatory execution risks while monitoring ongoing financing updates and filing milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers high-growth potential driven by late-stage clinical catalysts, tempered by clinical execution risks.
Momentum investorStrong fit while signal remains positiveStock price action is heavily dictated by binary clinical readouts and regulatory news flow.
Value investorWeak fitThe company lacks stable commercial revenues, traditional earnings, and positive cash flow.
Dividend investorWeak fitINmune Bio does not pay dividends and retains all capital for clinical development.
Low-risk investorWeak fitClinical-stage biotechnology stocks exhibit high volatility and binary trial risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical trial data releases and regulatory updates frequently trigger sharp share price swings.
Valuation riskMedium / highValuations are speculative and rely heavily on projected future commercialization success.
Competition risk (neuroscience and cell therapy)HighWell-funded competitors are developing alternative therapies for Alzheimer's disease and RDEB.
Business qualityMediumThe company possesses promising scientific platforms but lacks established commercial infrastructure.
Dividend incomeLow / noneNo dividend distributions are available or anticipated in the near term.
Execution riskHighSuccess depends entirely on navigating complex regulatory frameworks and clinical trials successfully.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 32.51M USD
Price to earnings Ratio -
1Y Target Price 6.5
Price to earnings Ratio -
1Y Target Price 6.5
Volume (30-day avg) 307.1K shares
Beta 0.94
52 Weeks Range 1.01 - 2.60
Updated Date 11/15/2026
52 Weeks Range 1.01 - 2.60
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.6

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -6.39%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
INMB receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
INMB has moderate overall fundamentals (3 stars), with moderate financial health, solid growth momentum, and moderate ownership. In FY2025 versus FY2024, strong revenue growth (+257.1%) is partially offset by negative earnings growth (-9.2%), weak cash generation (FCF margin -47248.0%), weak profitability (net margin -91866.0%).

Financial Health Rating

★★★★★
INMB's financial health is supported by moderate efficiency, including operating-expense and cost-of-revenue discipline (opex 61838.0% of revenue). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is INMB's strongest growth driver at +257.1% FY2025 versus FY2024 (strong, 5 stars). By comparison, free-cash-flow growth (+29.2%, solid) is also solid, while earnings growth (-9.2%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 16.4% (soft) and 90.2% of outstanding shares are publicly tradable (strong). Insider ownership of 9.71% supports management-shareholder alignment.

Top 5 Institutional Investors

Vanguard Capital Management, LLC 2.28%
AQR Capital Management LLC 2.14%
BlackRock Inc 1.01%
Renaissance Technologies Corp 0.96%
Geode Capital Management, LLC 0.61%

Unit Economics (Per $1K Revenue)

★★★★★
INMB generates approximately $1,000 of gross profit, $-617,380 of operating income, and $-472,480 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
INMB has a liquid profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Small / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical Development and TherapeuticsFuture commercial sales and out-licensing royalties from pipeline candidates such as CORDStrom and XPro upon regulatory approval.Currently a pre-revenue clinical stage company relying on grants, collaborations, and future product commercialization.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 17.23M
Price to Sales(TTM) -
Enterprise Value 17.23M
Price to Sales(TTM) -
Enterprise Value to Revenue 479.39
Enterprise Value to EBITDA -5.31
Shares Outstanding 30.96M
Shares Floating 27.94M
Shares Outstanding 30.96M
Shares Floating 27.94M
Percent Insiders 9.71
Percent Institutions 16.35

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.